The MYST family of histone acetyltransferases (HATs) was initially defined by human genes with disease connections and by yeast genes identified for their role in epigenetic transcriptional silencing. Since then, many new MYST genes have been discovered through genetic and genomic approaches. Characterization of the complexes through which MYST proteins act, regions of the genome to which they are targeted and biological consequences when they are disrupted, all deepen the connections of MYST proteins to development, growth control and human cancers. Many of the insights into MYST family function have come from studies in model organisms. Herein, we review functions of two of the founding MYST genes, yeast SAS2 and SAS3, and the essential yeast MYST ESA1. Analysis of these genes in yeast has defined roles for MYST proteins in transcriptional activation and silencing, and chromatin-mediated boundary formation. They have further roles in DNA damage repair and nuclear integrity. The observation that MYST protein complexes share subunits with other HATs, histone deacetylases and other key nuclear proteins, many with connections to human cancers, strengthens the idea that coordinating distinct chromatin modifications is critical for regulation.
The MYST family of histone acetyltransferases (HATs) was initially defined by human genes with disease connections and by yeast genes identified for their role in epigenetic transcriptional silencing. Since then, many new MYST genes have been discovered through genetic and genomic approaches. Characterization of the complexes through which MYST proteins act, regions of the genome to which they are targeted and biological consequences when they are disrupted, all deepen the connections of MYST proteins to development, growth control and human cancers. Many of the insights into MYST family function have come from studies in model organisms. Herein, we review functions of two of the founding MYST genes, yeast SAS2 and SAS3, and the essential yeast MYST ESA1. Analysis of these genes in yeast has defined roles for MYST proteins in transcriptional activation and silencing, and chromatin-mediated boundary formation. They have further roles in DNA damage repair and nuclear integrity. The observation that MYST protein complexes share subunits with other HATs, histone deacetylases and other key nuclear proteins, many with connections to human cancers, strengthens the idea that coordinating distinct chromatin modifications is critical for regulation. Oncogene (2007) 26, 5373-5384; doi:10.1038/sj.onc.1210606 Keywords: chromatin; transcription; Saccharomyces cerevisiae; silencing Overview Among the many chromatin modifications known, histone acetylation received particularly prominent early attention with the molecular identification of HAT1 and GCN5 as genes encoding histone acetyltransferases (HATs) (Kleff et al., 1995; Brownell et al., 1996; Parthun et al., 1996) . Although these two HATs have different substrate specificities, initial sequence comparisons revealed significant yet restricted similarity in regions predicted to bind acetyl-CoA. When additional genes were identified with potential roles in chromatinmediated gene control, even modest degrees of similarity to the acetyl-CoA-binding regions were viewed with special interest as candidate HATs.
Such interest was particularly the case when mutants of SAS2 (something about silencing) were discovered as enhancers of mutations in the epigenetic transcriptional silencer factor Sir1 (Reifsnyder et al., 1996) and suppressors of defects in cis-regulatory sequences for silent chromatin (Reifsnyder et al., 1996; EhrenhoferMurray et al., 1997) . The observation that SAS2 and the closely related SAS3 yeast genes shared similarity to acetyl-CoA-binding domains, and even more significant similarity to two human genes, MOZ (Borrow et al., 1996) and TIP60 (Kamine et al., 1996) , quickly led to the recognition that together these genes defined a broadly conserved family that was named MYST for its founding members (MOZ-YBF2/SAS3-SAS2-TIP60) (Borrow et al., 1996; Reifsnyder et al., 1996) . ESA1 was later identified as the third yeast MYST gene (Smith et al., 1998a; Clarke et al., 1999) with diverse functions: it is essential for viability, and plays roles in transcriptional activation, silencing, cell cycle progression and DNA damage repair.
The MYST domain -defined as the most conserved region in MYST family proteins -comprises a region that includes both the sequences surrounding the acetylCoA-binding domain and in most enzymes an atypical C2HC zinc finger. Whereas the sequence of the MYST core domain is well conserved in Sas3 and Sas2, Esa1 lacks three of the four amino acids for zinc binding. However, the crystal structure of Esa1 revealed that this region forms a classical TFIIIA-type zinc finger fold in the absence of zinc suggesting a structurally conserved core domain with other MYST HATs (Yan et al., 2000) . Besides the MYST domain, Sas3 and Esa1 contain additional conserved regions that are only found in subsets of the MYST family proteins, described below.
The early link between human MOZ, a recurrent translocation partner in several acute leukemias, and the three yeast genes implicated in chromatin-mediated transcriptional silencing raised the possibility that fundamentally conserved mechanisms might inform basic understanding between silencing mechanisms and human disease. As further genomic and genetic analyses proceeded, it became clear that the MYST family was broadly conserved. As of early 2007, several hundred related genomic sequences sharing significant sequence similarity over an B150 amino acid domain encompassing the acetyl-CoA-binding site have been annotated as MYST genes (http://www.ncbi.nlm.nih.gov/entrez/query. fcgi?db ¼ Protein). Among MYST proteins of particular note are the Drosophila MOF gene that is essential only in males for dosage compensation (Hilfiker et al., 1997) and the human MOF, MORF, MOZ and HBO1 genes that have been implicated in multiple aspects of human development and disease (Avvakumov and Coˆte´, 2007; Rea et al., 2007) .
Many insights into MYST gene functions came initially from studies in model organisms, including Drosophila, Caenorhabditis elegans, mouse, and the yeasts Saccharomyces pombe and Saccharomyces cerevisiae (described elsewhere in this issue and reviewed in Yang, 2004) . This progress has come from the open-ended nature of genetic screens, targeted gene deletion techniques and biochemical approaches combined with complete genome sequences and resources.
S. cerevisiae is a particularly rapid and informative genetic system for dissecting human protein function. For example, two-hybrid screening identified an interaction of the MYST protein HBO1 with progesterone receptor (PR) (Georgiakaki et al., 2006) , a member of the family of steroid receptors. This observation prompted further analysis in human cells, which showed that HBO1 enhancement of PR-dependent transcription required steroid receptor coactivator SRC-1 (Georgiakaki et al., 2006) . Steroid receptors and their coactivators are key regulators of gene expression (Lonard and O'Malley, 2006) and participate in signaling pathways susceptible to misregulation in cancer cells. Yeast assays can be designed also to study mechanisms of coactivator function. For example, phenotypes conferred upon expression of hSRC-3 (Brown et al., 2003) , GRIP1 and SRC-1 (Anafi et al., 2000) revealed a role for Gcn5 HAT complex components. These and other ingenious yeast assays will lend further insight into mechanisms underlying human MYST HAT function. The clinical implications of these observations can be further tested in yeast screens to identify chemicals that interact with steroid hormones and coactivators to modulate their transcriptional output (Nishikawa et al., 1999) and correlate mutations in key cancer-associated proteins with mutations that are clinically relevant, as was the case with p53 mutant screens in yeast (Brachmann et al., 1996) .
An underlying principle of screening human protein function in yeast is that their function is conserved. Recent advances defining human MYST complexes underscore this conserved molecular nature (Avvakumov and Coˆte´, 2007) that is often mirrored in conserved function. Although yeast has a simpler MYST repertoire than humans, it is likely that ongoing studies will continue to identify additional histone and non-histone substrates, mechanisms for regulation and, ultimately, pharmacological modulators with therapeutic significance.
In this review, we begin by considering each of the S. cerevisiae MYST genes and proteins individually.
Here, their structural and functional distinctions are briefly highlighted in three categories: (1) definitions of histone substrate specificity À of particular interest are disease-relevant non-histone substrates such as p53 in humans (Sykes et al., 2006; Tang et al., 2006) , (2) the MYST multi-protein complex(es) that modulate enzymatic activity and promote coregulation with other chromatin remodeling complexes through shared subunits and (3) the gene-specific versus global acetylation patterns that are of critical importance for disease and assessing potential success and side effect of therapeutic agents. These aspects are considered in more detail in other recent reviews (Utley and Coˆte´, 2003; Yang, 2004; Altaf et al., 2007) . We go on to address yeast MYSTs in the context of human disease, illustrated by mutant phenotypes and conserved complex subunits. Further, we consider what has been learned from genomic and proteomic surveys in yeast and speculate on what may be learned from future studies that will be relevant for understanding human health and disease.
SAS3: critical functional links to GCN5 and H3 modifications SAS3 is arguably the least well-understood MYST gene in yeast. In large part, this is because of the lack of extreme phenotypes observed upon deletion; indeed, SAS3 was originally reported to have only minor functions in silencing at mating-type loci (Reifsnyder et al., 1996) .
Sas3 contains extensive stretches of acidic aspartate and glutamate residues in its C-terminus region, also found in the human MYST HATs MOZ and MORF. Although the functional significance of this domain in the human proteins remains unclear, the acidic domain of Sas3 is required for its physical interaction with the essential transcriptional elongation factor Spt16 through two-hybrid screening (John et al., 2000) . This suggests a function of Sas3 in transcriptional regulation mediated by RNA polymerase II.
Although much remains to be learned of the biological processes regulated by SAS3, the determinants of its molecular function have been well characterized, including the multi-protein complex containing Sas3 and the histone residues it targets. Sas3 is the catalytic subunit of the large multi-protein complex named NuA3 (for Nucleosomal Acetylation of H3) (John et al., 2000) . This complex (Figure 1 and Table 1 ) contains the Sas3 enzyme plus four subunits clearly identified as stable components: (1) the TBP-associated factor Taf14; (2) the Yeast iNhibitor-of-Growth protein Yng1; (3) Eaf6, first identified as an Esa1-associated factor and (4) the NuA Three ORF, Nto1 (John et al., 2000; Howe et al., 2002; Doyon et al., 2004; Krogan et al., 2006; Taverna et al., 2006) . Of note, two of these NuA3 components are shared by other complexes whose function is linked to chromatin (a feature observed for other NuA4 (Nucleosomal Acetylation of H4) complex components whose catalytic subunit is Esa1, see below): Taf14 is also a component of the transcription-related complexes TFIID, TFIIF, INO80, mediator and SWI/SNF complexes; Eaf6 is part of the NuA4 complex . Although several other potential NuA3 components have been identified by mass spectrometry (John et al., 2000) , their validation awaits further study.
The characterization of the enzymatic activity of Sas3 -as a purified recombinant protein as well as part of the NuA3 complex in vitro and in vivo -established HAT activity toward histone H3 (Takechi and Nakayama, 1999; John et al., 2000; Howe et al., 2001) . Furthermore, lysine 14 of histone H3 (H3-K14) was identified as the primary substrate of the NuA3 complex in vitro and in vivo , and of note, this is also a preferred substrate of Gcn5 (Baker and Grant, 2007) .
Additional clues about the biological function of Sas3 are provided by the synthetic lethal interaction between mutants of SAS3 and GCN5 . Gcn5 is a member of the GNAT family of acetyltransferases and shares overlapping patterns of acetylation with Sas3. Simultaneous disruption of SAS3 and GCN5 is synthetically lethal due to the loss of acetyltransferase activity. This synthetic lethal interaction establishes that histone H3 acetyltransferase activity contributes to viability in yeast, and builds on earlier mutational studies demonstrating critical, yet perhaps redundant roles for acetylation of either H3 or H4 tails (reviewed in Grunstein, 1990) . Furthermore, loss of GCN5 combined with several mutant alleles of SAS3, including deletion of the aspartate/glutamate C terminus, results in conditional arrest in the G 2 /M phase of the cell cycle, demonstrating a role for Sas3 in cell cycle regulation.
In support of such a function, Sas3 has been reported to physically interact with the Chk1 DNA-damage effector kinase that mediates mitotic cell cycle arrest (Liu et al., 2000) .
Two recent papers provided new insight on the molecular function of the NuA3 complex, and further uncovered a specific role of the NuA3 complex component, Yng1 (Martin et al., 2006; Taverna et al., 2006) . A previous study established that Yng1 is required for NuA3 function by promoting interaction of Sas3 with nucleosomes (Howe et al., 2002) . The recent studies further characterized this interaction to show that Yng1 binds nucleosomes that have been methylated by Set1 and Set2 at H3-K4 and H3-K36, respectively (Martin et al., 2006; Taverna et al., 2006) . Furthermore, it was observed that Yng1 binding promotes NuA3 HAT activity at K14-targeted genes. These results and the enrichment of H3-K4me3 at the 5 0 end of transcriptionally active open reading frames (Pokholok et al., 2005) support a role for NuA3 in transcriptional activation.
SAS2: distinct functions at chromatin-mediated barriers for heterochromatin
Compared with SAS3, more studies have focused on SAS2 as its deletion results in several clear effects on transcriptional silencing (Reifsnyder et al., 1996; Ehrenhofer-Murray et al., 1997; Meijsing and Ehrenhofer-Murray, 2001 ). In addition to phenotypic differences in the mutants, Sas2 also differs in its histone substrate specificity, HAT-associated multi-protein complexes and the cellular processes it regulates.
Sas2 is the catalytic subunit of the SAS complex that also includes Sas4 and Sas5 (Meijsing and EhrenhoferMurray, 2001; Osada et al., 2001; Sutton et al., 2003) ( Figure 2 and Table 1 ). The acetyl-CoA-binding domain of Sas2 is essential for the enzymatic activity of the SAS complex, in which deletion or mutations produce the same phenotype (Meijsing and Ehrenhofer-Murray, 2001; Osada et al., 2001) . Sas4 is required for HAT activity of Sas2, whereas Sas5 increases HAT activity in vitro, although is not essential for complex function (Sutton et al., 2003) .
In contrast to NuA3, in vitro experiments show that the SAS complex acetylates histone H4 at K16 and contributes extensively to the bulk of H4-K16 acetylation in vivo (Kimura et al., 2002; Shia et al., 2006) . In parallel, mutation of H4-K16 mimics sas2D phenotypes (Meijsing and Ehrenhofer-Murray, 2001 ). Whereas Sas3 and Sas2 have the same role in HMR mating-type transcriptional silencing, early studies on Sas2 function uncovered a more significant role promoting silencing at HML and telomeres (Reifsnyder et al., 1996; Ehrenhofer-Murray et al., 1997; Xu et al., 1999b) .
The mechanism of Sas2 function in telomeric silencing reveals a crucial role in establishment of silencing barriers in concert with the histone deacetylase (HDAC) Sir2 (Kimura et al., 2002; Suka et al., 2002) . The two proteins oppose each other in H4-K16 acetylation to establish a modification gradient along the chromosome, from a hypo-acetylated state at the telomeres to a hyper-acetylated state in more distal regions. The establishment of this barrier requires both H4-K16 acetylation and deacetylation activities mediated by Figure 1 The NuA3 complex. NuA3 is a B450 kDa complex that acetylates lysine residues on histone H3. The NuA3 complex is not yet fully characterized, and contains at least five known subunits, of which Sas3 (in yellow) is the catalytic HAT. At least three of the five subunits of NuA3 are related to human oncogenes or tumor suppressors and are further described in Table 1 . Subunits are categorized as: Level 1, human homologs that are mutated in cancers; Level 2, associated with cellular processes commonly defective or inactivated in cancer cells, such as cell cycle regulation and DNA damage repair. HAT, histone acetyltransferase.
Sas2 and the HDAC Sir2, respectively (Kimura et al., 2002; Suka et al., 2002) .
In addition, the HAT activity of SAS in sub-telomeric regions is required for efficient H2A.Z incorporation near telomeres. The presence of H4-K16 acetylation and H2A.Z synergistically prevent the ectopic propagation of heterochromatin into transcriptionally active regions (Shia et al., 2006) .
A key function of the SAS complex is also mediated through replication-coupled chromatin assembly. Indeed, physical and genetic interactions have been established between the SAS complex and two chromatin assembly factors Asf1 and Cac1, suggesting that the SAS complex is recruited to freshly replicated DNA to acetylate H4-K16 during assembly (Meijsing and Ehrenhofer-Murray, 2001; Osada et al., 2001) . This interaction seems to be particularly important for silencing at the cryptic HM mating-type loci as the Abbreviations: CPT, camptothecin; HU, hydroxyurea; MMS, methyl methanesulfonate; UV, ultraviolet radiation. Subunits are listed alphabetically within each complex, and those with direct disease parallels (Level 1 in Figures 1-3) are highlighted in bold. The piccolo subunits are marked with an * in the NuA4 section. Relevant phenotypes of yeast mutants are noted and are further described and referenced at Saccharomyces Genome Database (www.yeastgenome.org). Listed references are restricted to those not already mentioned in the text. Figure 2 The SAS complex. The SAS complex is the smallest of the MYST complexes in yeast, and at 125 kDa is composed of three subunits. Sas2 (in yellow) is the catalytic subunit, whereas Sas4 and Sas5 are important for specificity, complex integrity and optimal activity. Sas5 contains a YEATS domain, found in human leukemogenic proteins. All of these subunits are further described in Table 1 . Levels 1 and 2 are as defined in Figure 1 ; Level 3 disease associations have not yet been characterized, but mutant phenotypes and functions provide clues for future study.
Yeast MYST HATs and human cancer A Lafon et al ASF1-dependent localization of the SAS complex is required for SIR1-dependent HML silencing (Osada et al., 2001) . In addition to these chromatin assembly factors, the origin recognition complex (ORC) that is essential for DNA replication appears to be a key element for the establishment of silencing at matingtype loci mediated by Sas2. This link was defined by interactions between Sas2 and the ORC proteins Orc2 and Orc5 in the establishment of transcriptionally repressed chromatin (Ehrenhofer-Murray et al., 1997).
The requirement for the ORC complex in promoting silencing appears to be independent of its replicative role (Kirchmaier and Rine, 2001; Li et al., 2001) and is still being defined mechanistically. In sum, study of Sas2 reveals an intriguing function in maintaining heterochromatin boundaries that demarcate specialized silenced regions of chromatin from those that are transcriptionally active. This function involves physical and genetic interactions with other chromatin-related complexes/proteins, the HDAC Sir2, the chromatin assembly factors Asf1 and Cac1, and the ORC complex.
Although not yet reported, similar boundary functions may be dependent on MYST protein complexes in humans, since many of the factors are themselves conserved and maintenance of heterochromatic and euchromatic regions is an integral part of human development and gene regulation.
ESA1: an essential MYST linking essential cellular processes
Several key distinctions set ESA1 apart from the other yeast MYST genes. These include the essential nature of ESA1 and the large spectrum of cellular processes it regulates, described below. Another key feature is that Esa1 is the catalytic subunit of two distinct multiprotein complexes: NuA4 and piccolo ( Figure 3 and Table 1 ).
NuA4 is the largest MYST complex in yeast, containing Esa1 and 12 other subunits. Among the best characterized components of the NuA4 complex are Tra1, the essential ATM-family cofactor that facilitates recruitment of NuA4 (Allard et al., 1999; Brown et al., 2001) ; Yng2, an inhibitor-of-growth 1 (ING1) tumor suppressor homolog, involved in cell cycle progression and DNA-damage response (Choy et al., 2001; Choy and Kron, 2002) ; Arp4, an essential actin-related protein with roles in gene-specific transcription regulation (Galarneau et al., 2000) ; and Epl1, an essential homolog of the Drosophila Enhancer of Polycomb, involved in cell cycle progression through G 2 /M (Boudreault et al., 2003) . The piccolo complex is a subset of the NuA4 complex with very high HAT activity toward nucleosomes that consists of three subunits, Esa1, Yng2 and Epl1 (Boudreault et al., 2003) .
As described above for the NuA3 complex, several components of NuA4 are shared with chromatin-related complexes. Arp4 is present in the INO80 chromatin remodeling complex (Shen et al., 2003) and along with two other subunits, Yaf9 and Act1, is part of the SWR1 complex that deposits the Htz1 histone variant into chromatin (Krogan et al., 2003 (Krogan et al., , 2004 Kobor et al., 2004) . Moreover, NuA4 shares Tra1 with two Gcn5-contining HAT complexes, SAGA and SLIK. In both the SAGA and NuA4 complexes, Tra1 targets the HAT complexes to their proper promoter-specific sites of acetylation through physical interactions with transcription activators .
Among the MYST complexes, NuA4 displays extended histone substrate specificity as it acetylates preferentially histones H4 and H2A on nucleosomal templates (Allard et al., 1999) . In vitro experiments with recombinant Esa1 demonstrates activity on H4, H3 and H2A core histones (Smith et al., 1998a; Clarke et al., 1999) ; in vivo Esa1 is responsible for much of H4-K5 acetylation . On promoters of candidate genes, Esa1 acetylates all sites tested on H4, H2A and H2B tails, except H4-K16 (Suka et al., 2001) . NuA4 also mediates acetylation of H2A.Z after its incorporation by the SWR1 complex (Babiarz et al., 2006; Keogh et al., 2006; Millar et al., 2006) .
The essential nature of Esa1 illustrates the critical functions performed by this MYST protein in numerous chromatin-dependent processes (Smith et al., 1998b; Clarke et al., 1999) . Indeed, Esa1 plays a crucial role in cell cycle progression through G 2 /M as an esa1 conditional mutant proceeds through DNA replication but fails to complete mitosis and cytokinesis . This arrest is dependent on the RAD9-mediated DNA damage checkpoint as RAD9 deletion prevents esa1 mutant G 2 /M arrest, but does not significantly affect loss of viability, suggesting additional roles for Esa1. One mechanism underlying these phenotypes is that acetylation of histone H4 by Esa1 is required for DNA double-strand break repair (Bird et al., 2002) . Moreover, the NuA4 subunit Arp4 is recruited in vivo to the site of DNA double-strand Figure 3 The NuA4 complex. The NuA4 complex is 1.3 MDa and contains six subunits that are essential for viability (shown as bold outline), with Esa1 (in yellow) as the catalytic HAT. Many of the components are related to human disease genes and are present in other chromatin modification complexes. Piccolo is a distinct Esa1 complex containing a subset of three NuA4 subunits. The piccolo subunits are underlined. Levels 1-3 are as defined in Figures 1 and  2 . These subunits are further described in Table 1 .
Yeast MYST HATs and human cancer A Lafon et al breaks (Bird et al., 2002; Downs et al., 2004) . Esa1 itself localizes to DNA double-strand breaks as well (Tamburini and Tyler, 2005) .
Esa1's function in transcriptional activation has been studied at a genome-wide level and with individual target gene validation (Reid et al., 2000) , revealing a clear role in transcription of growth-essential ribosomal protein genes. In addition to promoting transcription, Esa1 also functions in telomeric and rDNA silencing (Clarke et al., 2006) . Indeed, Esa1 is important for maintaining nucleolar structure as revealed by altered localization of Nop1 and Sir2 nucleolar proteins and differences in pulsed-field gel electrophoresis of chromosomes and ultrastructural profiles in esa1 mutants (Clarke et al., , 2006 . Like Sir2, Esa1 is enriched at rDNA and both mutants are defective in rDNA silencing. In contrast to sir2D, esa1 loss of function slightly increases the recombination rates in rDNA. The overexpression of ESA1 can bypass the requirement for Sir2 in rDNA silencing, suggesting that these two proteins with opposing enzymatic activities both contribute to proper nucleolar structure and function (Clarke et al., 2006) .
A genome-wide analysis of Esa1 occupancy in yeast revealed that this MYST protein is generally recruited to the promoters of active protein-encoding genes (Robert et al., 2004) , which correlates well with earlier studies (Reid et al., 2000) . Several candidate target genes have been examined in detail. For example, Esa1 was shown to occupy and acetylate the PHO5 promoter, resulting in transcriptional activation (Vogelauer et al., 2000; Nourani et al., 2004) .
The MYST HATs: yeast answers and cancer insights
The individual summaries above of each yeast MYST HAT and the complex(es) through which they act highlight the fundamental, and likely conserved functions for the family of enzymes. How can this information help us think about cancers in humans that may be influenced by acetylation and other processes controlled by MYST proteins? A starting point for the answer to this question comes from the enzymes themselves and their conserved complex subunits that have been correlated with various pathologies and developmental defects in metazoans.
Correlating yeast and human MYSTs
By both molecular architecture and sequence identity, Esa1 appears most closely related to the human Tip60 protein because of their overall structures. This includes the shared N-terminus chromodomains (CHDs), the MYST domain itself and considerable sequence similarity throughout the remainder of the two proteins. Esa1 is the only yeast MYST to possess a CHD, also found in human and Drosophila MOF. In dMOF, the CHD contributes to RNA binding (Akhtar et al., 2000) , and in Esa1 is critical for growth and some aspect of catalysis after nucleosome binding (Selleck et al., 2005) . The CHD function is not yet clearly defined in the human MYST proteins, although many CHDs appear to bind methylated histones (reviewed in Daniel et al., 2005) . Like Esa1, Tip60 has clear roles in transcriptional activation and silencing, and distinct functions in DNA damage and repair (Avvakumov and Coˆte´, 2007) .
But what of Sas2 and Sas3? Identification of human orthologs is somewhat less direct because neither yeast enzyme has a strikingly similar combination of other domains, such as paired PHD (Plant HomeoDomain) boxes, or H15 domains that characterize some of the human proteins. However, several features of each yeast protein ally them with distinct human MYSTs. Sas3 has the longest C-terminus extension flanking the MYST domain, and like MOZ and MORF, this region is notably aspartate and glutamate rich. Sas3 has a marked preference for H3 acetylation, whereas the human proteins acetylate both H3 and H4. In contrast to the dearth of sas3 null phenotypes, recurrent reciprocal translocations of MOZ or MORF to chromatin-modifying genes including CBP, p300 and TIF2 occur in patients with acute myeloid leukemia (AML). Both in vitro and in vivo studies indicate that the fusion proteins arising from these translocations are the causative agent of cancer, apparently by interfering with the activities of key regulatory proteins including nuclear receptors, the tumor suppressor p53 and Runx proteins (reviewed in Yang, 2004; Troke et al., 2006) .
Sas2 also shares similarities with more than one human MYST. Sas2 HAT activity is restricted to H4, similar to the human MOF, and BLAST sequence analysis of yeast Sas2 with default settings returns hMOF as the top hit. Studies of MOF in Drosophila have revealed an important enzymatic role in the male specific lethal (MSL)-containing dosage compensation complex. MOF increases H4-K16 acetylation and transcription of the single male X chromosome (Hilfiker et al., 1997; Smith et al., 2000) . A human MSL-like complex containing hMOF has been identified and functions in cell cycle progression (Smith et al., 2000) . It will be interesting to see how this function is related to the hMOF interaction with ATM, a protein important in DNA damage responses (Gupta et al., 2005) .
Sas2 also shares conserved interacting partners with the human MYST HBO1 that manifest in different phenotypes at the organismal level (Avvakumov and Coˆte´, 2007) . Perhaps Sas2 melds features and functions of both MOF and HBO1, as appears to be the case for the S. pombe mst2 þ (Go´mez et al., 2005 ) when compared to S. cerevisiae Sas2 and Sas3.
Also of note are Sas2's functional interactions with members of the ORC replication complex (EhrenhoferMurray et al., 1997; Meijsing and Ehrenhofer-Murray, 2001 ) and postreplication chromatin assembly factors (Osada et al., 2001) . These are paralleled by interactions of human HBO1 with ORC (Iizuka and Stillman, 1999) . Whereas the Sas2 and replication protein interactions underlie epigenetic regulation of gene expression in yeast, HBO1 interactions seem more clearly tied to replication origin function. One of the earliest observations Yeast MYST HATs and human cancer A Lafon et al that revealed this important link to cell proliferation was that HBO1 associates with both hORC1 (Iizuka and Stillman, 1999) and MCM2 (Burke et al., 2001 ) in mammalian cells and may be important in forming a functional replication complex (Iizuka and Stillman, 1999; Iizuka et al., 2006) . Furthermore, HBO1 interacts with ING4 and ING5 (Doyon et al., 2006) , and CDK11 (Zong et al., 2005) to regulate cell cycle progression. Although human cancers directly implicating HBO1 have not been reported, this area of research will be important in understanding fundamental mechanisms of cell cycle control that have gone awry in cancers, in addition to HBO1's known involvement in gene expression through interaction with transcription factors (Sharma et al., 2000; Sterner and Berger, 2000) .
Parallels in MYST complexes
In defining the yeast MYST complex subunits above, note was made of similar subunits shared among them. Equally striking are the number of subunits with human homologs that are themselves associated with specific human cancers and/or tumor suppressors. This point is highlighted by the color scheme for the complexes in Figures 1-3 , in which noncatalytic subunits with human homologs are shaded to denote different levels of disease association. Some MYST complex members have obvious homologs that are specifically related to a type of cancer, whereas others have roles in processes that are defective in cancers, such as DNA damage repair, and cell cycle control (Table 1) . Many members of the yeast MYST complexes are conserved in mammals, establishing a link between the human proteins and the transcriptional activation function of the yeast proteins. It should be noted that there is both conservation of individual subunits from yeast to humans, and that the whole complex appears conserved. When mutated, many of these human proteins become oncogenic (Ogryzko, 2001; Timmermann et al., 2001) . Indeed, studies of yeast chimeric proteins mimicking the MOZ translocation fusion partners found in some AML patients show that they can misregulate gene expression upon aberrant chromosomal targeting (Jacobson and Pillus, 2004) . Thus, further analysis of the yeast phenotypes may become even more informative in dissecting the mechanisms underlying oncogenesis.
There are three YEATS domain (defined by the first proteins in which it was found (Yaf9-Enl-AF9-Taf14-Sas5)) proteins in yeast: Taf14, Sas5 and Yaf9, each of which participates in a distinct MYST complex. Although each individual null mutant is viable, deleting all three genes results in cell death, demonstrating that at least one domain is essential (Zhang et al., 2004) . Human proteins with YEATS domains include Enl and AF-9, dysfunction of which is associated with leukemias (reviewed in Zhang and Rowley, 2006) . These are also recurrent translocation partners with the MLL gene (Slany et al., 1998; Schreiner et al., 1999; Zeisig et al., 2004) . AF-9 interacts with another human chromatin-modifying enzyme, the histone methyltransferase Dot1 . Although interaction with yeast Dot1 has not yet been reported for Taf14, Sas5 or Yaf9, it appears that a role in histone modification for YEATS domain proteins is conserved.
Taf14 is the YEATS protein in NuA3, and is a component of multiple chromatin-modifying complexes, as noted above. Mutant taf14D cells are sensitive to DNA-damaging agents (Cairns et al., 1996; Kabani et al., 2005) . Like yeast Taf14, human GAS41 (glioma amplified sequence 41, also known as YEATS4) is reported to interact with INI1, the human homolog of Snf5, a subunit of the SWI/SNF complex (Debernardi et al., 2002) . This is another example of conserved roles for YEATS proteins.
Sas5, the YEATS domain-containing member of the SAS complex (Xu et al., 1999a; Osada et al., 2001) , is essential for complex integrity and HAT activity (Xu et al., 1999b; Osada et al., 2001; Shia et al., 2005) . It has been suggested that YEATS domain proteins may play a role in targeting their complexes to chromatin boundaries (Zhang et al., 2004) , a model which if correct would explain why they are often found associated with silencing or anti-silencing factors.
Yaf9, a component of NuA4, was named for its similarity to the AF-9 human leukemogenic protein although it is now recognized to be more similar to GAS41 (Le Masson et al., 2003) . Mutant YAF9 phenotypes suggest a role in DNA repair (Bittner et al., 2004; Zhang et al., 2004) and Yaf9 is also part of the SWR1 complex (Kobor et al., 2004; Krogan et al., 2004) . Yaf9 binds to Swc4, a NuA4 and SWR1 complex component that is the homolog of mammalian DNA methyltransferase-associated protein 1, DMAP1 (Doyon et al., 2004) .
Aside from the YEATS proteins, there are several other yeast MYST complex members that share homology to cancer-related genes. Whereas some of these have homology with potential oncogenes, others resemble human tumor suppressors. The NuA4 subunit Yng2 and the NuA3 subunit Yng1 share homology with the human ING tumor suppressor family.
Studies by Nourani and colleagues use human p53 expressed in yeast cells to examine the effect of yeast MYST genes on p53's function as a transcriptional activator. Both human and yeast ING homologs can modulate p53 activity. Yng2 is the yeast homolog of the human Ing1/p33 tumor suppressor, and is required for p53-dependent transcription ). This demonstrates the broad functional conservation of the ING proteins from yeast to humans. Since p53 has functions in both transcriptional activation and DNA damage response, there may be many further connections between p53 and histone-modifying complexes. Human p53 interacts with NuA4 in vivo in yeast cells , just as p53 interacts with ING1 in human cells. p53 is acetylated by the human Tip60 H4/ H2A HAT complex (Sykes et al., 2006; Tang et al., 2006) , the homolog of NuA4. Tip60 and p53 mutants are sensitive to DNA damage (Legube et al., 2004) , likewise YNG2 mutant phenotypes are suggestive of a role in DNA damage response (Choy and Kron, 2002) . In contrast to Yng2's role in promoting p53-dependent transcription, Yng1 in NuA3 was observed to inhibit p53 transcription. In both yng1D and sas3D mutants, p53-dependent transcription is increased (Nourani et al., 2003) .
A clear human homolog for the NuA4 component Tra1 is TRAAP. TRA1 is essential for viability in yeast (Saleh et al., 1998) , and its overexpression rescues mcm5/cdc46 mutants. MCM5 encodes a protein that functions not only in DNA replication, but like Esa1, has a role in transcriptional silencing (Dziak et al., 2003) . Tra1 is also a component of the SAGA and SLIK Gcn5-containing HAT complexes, similarly, TRAAP is associated with PCAF and GCN5 HATs in human cells (Grant et al., 1998; Pray-Grant et al., 2002; Sterner et al., 2002) . This conserved association with transcriptional activators (Vassilev et al., 1998) is also exemplified by the ability of TRAAP to interact with c-Myc and E2F-1 to promote their oncogenic potential reviewed in Murr et al., 2007) .
A less well-studied component of NuA3 is Nto1, which was only recently reported to be part of the complex (Taverna et al., 2006) . Its precise function is not yet known, but it is similar to human Jade and BRPF proteins (Doyon et al., 2006) . Human Jade is part of the HBO1 MYST HAT complex, whereas BRPF is a MOZ/ MORF complex component. Jade itself has close connections to human cancer, as it is reported to interact with the von Hippel-Lindau tumor suppressor as well as human Tip60 (Zhou et al., 2002; Panchenko et al., 2004) .
Other yeast MYST complex components have clear molecular homologs in humans (Table 1) , but have not yet been extensively studied. However, their mutant phenotypes and in some cases essential nature in yeast suggest potential for critical functions in humans, many of which have roles in cancer processes. It may be useful to consider these under-studied homologs with high priority as candidate disease genes or for knockdown studies.
Genomic and proteomic studies in yeast provide clues for the future The completion of the S. cerevisiae genome as the first eukaryotic full-DNA sequence provided a platform for the pioneering development of large-scale genomic and proteomic tools. These allowed analysis of individual genes, as well as evaluation of organismal effects of mutations and physiological perturbations. As the human genome sequence was completed and its annotation becomes increasingly refined, much of the progress made with yeast will be useful in directly informing us about human gene functions and providing hypotheses for mechanisms of disease.
Some of the notable successes and pioneering studies in yeast have been in the development of expression arrays that have subsequently been combined with genome-wide mapping of binding sites for chromatinmodifying enzymes. In concert with genome-wide maps of chromatin modifications themselves, it has been possible to devise detailed interaction network models that integrate sites of action and transcriptional effects of many different chromatin modifiers. For example, such an analysis has been performed for Esa1 (Robert et al., 2004; Pokholok et al., 2005) . This data set provides insights into acetylation, deacetylation and methylation, and should prove useful in defining conserved human target genes and global effects on modification that may be especially relevant when thinking about nontranscription-based functions, such as DNA repair.
Genome-wide protein interaction maps that have been developed through both affinity-tagging strategies and two-hybrid assays provide additional resources for thinking about uncharacterized human proteins with yeast homologs. Access to these data sets are readily available at the Saccharomyces Genome Database (http://www.yeastgenome.org), where simple gene-specific searches provide consolidated information with links to primary sources. In combination with genomewide mutant analyses (SGA and SLAM analyses, see Tong et al., 2001; Ooi et al., 2006) , powerful physical and functional interaction maps in yeast now exist. From these studies, many additional MYST complexinteracting proteins have been found. Although, they do not appear to be stable components of the biochemically purified complexes, they may prove to be important regulatory or targeting factors. Because these additional MYST-implicated factors have conserved homologs, they point to molecules that are worthy of closer examination in human cells and disease models.
Where especially clear functional correlations are possible, yeast may be a fruitful platform for small molecule and natural product screening for potential pharmacological modulators of activity (Bedalov et al., 2001; Grozinger et al., 2001; Olaharski et al., 2005) , as has proven of value in the sirtuin deacetylases. The sirtuin deacetylases and the MYST HATs are broadly conserved chromatin modifiers that deserve increased attention as therapeutic targets.
Although the primary focus on MYST protein function has been acetylation, studies in yeast described above are already pointing to clear functional relationships with other classes of modifiers, including deacetylases and methyltransferases. Understanding interactions and synergy of modifications will ultimately provide even more refined approaches for understanding mechanisms of disease and potential combinatorial therapeutics for their management.
